{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:41:56Z","timestamp":1790440916930,"version":"4.1.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:p>\n                    The aim of this study was to study the molecular epidemiology of 16S rRNA-methylase (RMT)-producing clinical\n                    <jats:italic toggle=\"yes\">Acinetobacter baumannii<\/jats:italic>\n                    isolates from hospitals in Athens, Greece. Single-patient\n                    <jats:italic toggle=\"yes\">A. baumannii<\/jats:italic>\n                    clinical isolates, coresistant to amikacin and gentamicin (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    \u2009=\u2009347), from five tertiary care hospitals, were submitted to minimum inhibitory concentration determination and molecular testing for carbapenemase and RMT genes.\n                    <jats:italic toggle=\"yes\">A. baumannii,<\/jats:italic>\n                    resistant to amikacin and gentamicin, was isolated at participating institutions at a mean rate of 67.8%. Among them 93.7% harbored the\n                    <jats:italic toggle=\"yes\">armA<\/jats:italic>\n                    . The vast majority (98.5%) of\n                    <jats:italic toggle=\"yes\">armA<\/jats:italic>\n                    positive isolates were OXA-23 producers, assigned mainly (99.4%) to sequence group G1, corresponding to international clone (IC) II. Four isolates (all from the same hospital) were OXA-24 producers (1.2%), assigned to G6 corresponding to CC78 and only one isolate was OXA-58-producer, assigned to G2 (IC I). Apramycin was the most active agent inhibiting 99.7% of the isolates at \u226464\u2009mg\/L, whereas colistin, trimethoprim\/sulfamethoxazole, minocycline, and tigecycline exhibited only sparse activity (S, &lt;18%). RMT production is an emerging mechanism of resistance, capable of compromising the clinical efficacy of aminoglycosides. High prevalence of\n                    <jats:italic toggle=\"yes\">armA<\/jats:italic>\n                    was observed among\n                    <jats:italic toggle=\"yes\">A. baumannii<\/jats:italic>\n                    strains isolated in participating hospitals in Athens, which were mainly OXA-23 producers and belonged to IC II. Apramycin is a structurally unique aminoglycoside, currently used as a veterinary agent. Although it has not been evaluated for clinical use, apramycin appears worthy of further investigation for repurposing as a human therapeutic against difficult-to-treat pathogens.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2019.0075","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T10:44:15Z","timestamp":1565261055000},"page":"9-13","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Dissemination of International Clone II\n                    <i>Acinetobacter baumannii<\/i>\n                    Strains Coproducing OXA-23 Carbapenemase and 16S rRNA Methylase ArmA in Athens, Greece"],"prefix":"10.1177","volume":"26","author":[{"given":"Konstantina","family":"Nafplioti","sequence":"first","affiliation":[{"name":"4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Galani","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece."},{"name":"4th Department of Internal Medicine, \u201cAttikon\u201d University General Hospital, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evdokia","family":"Angelidis","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Adamou","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Moraitou","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, \u201cSotiria\u201d General and Chest Diseases Hospital, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Giannopoulou","sequence":"additional","affiliation":[{"name":"Microbiology Department, \u201cThriasio\u201d General Hospital of Elefsina, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi","family":"Chra","sequence":"additional","affiliation":[{"name":"Microbiology Department, Korgialenio Benakio Hellenic Red Cross Hospital, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Damala","sequence":"additional","affiliation":[{"name":"Microbiology Department, \u201cAlexandra\u201d General Hospital of Athens, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangellos","family":"Vogiatzakis","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, \u201cSotiria\u201d General and Chest Diseases Hospital, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftheria","family":"Trikka-Graphakos","sequence":"additional","affiliation":[{"name":"Microbiology Department, \u201cThriasio\u201d General Hospital of Elefsina, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Baka","sequence":"additional","affiliation":[{"name":"Microbiology Department, Korgialenio Benakio Hellenic Red Cross Hospital, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Prifti","sequence":"additional","affiliation":[{"name":"Microbiology Department, \u201cAlexandra\u201d General Hospital of Athens, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Antoniadou","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece."},{"name":"4th Department of Internal Medicine, \u201cAttikon\u201d University General Hospital, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Souli","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,1,10]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/iub.534"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000708"},{"key":"e_1_3_4_4_2","first-page":"328","volume-title":"Principles and Practice of Infectious Diseases","author":"Gilbert D.N.","year":"2005","unstructured":"Gilbert D.N. 2005. Aminoglycosides. In Mandell G.L., , Bennett J.E., , and Dolin R. (ed.), Principles and Practice of Infectious Diseases. 6th ed. Churchill Livingstone, New York, p. 328.","edition":"6"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/518605"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00572-10"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03738.x"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2013.03.006"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.08.002"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3801-1"},{"key":"e_1_3_4_11_2","unstructured":"CLSI. 2012. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard\u20149th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_4_12_2","unstructured":"CLSI. 2018. Performance Standards for Antimicrobial Susceptibility Testing. 28th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_4_13_2","unstructured":"NCCLS. 2004. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Informational Supplement. NCCLS document M31-S1. National Committee for Clinical Laboratory Standards Wayne PA."},{"key":"e_1_3_4_14_2","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. 2019. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0. Available at www.eucast.org"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.03.006"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01759.x"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01911.x"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02263-09"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr390"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.2807\/ese.17.11.20117-en"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.01.028"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2012.06.001"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05678-11"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2006.05.002"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.03.001"},{"key":"e_1_3_4_27_2","first-page":"1031","article-title":"Variants of AbGRI3 carrying the armA gene in extensively antibiotic-resistant Acinetobacter baumannii from Singapore","volume":"72","author":"Blackwell G.A.","year":"2017","unstructured":"Blackwell G.A., , Holt K.E, , Bentley S.D, , Hsu L.Y, , and Hall R.M. 2017. Variants of AbGRI3 carrying the armA gene in extensively antibiotic-resistant Acinetobacter baumannii from Singapore. J. Antimicrob. Chemother. 72:1031\u20131039.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_4_28_2","article-title":"New treatment options against carbapenem-resistant Acinetobacter baumannii infections","volume":"63","author":"Isler B.","year":"2018","unstructured":"Isler B., , Doi Y., , Bonomo R.A, , and Paterson D.L.. 2018. New treatment options against carbapenem-resistant Acinetobacter baumannii infections. Antimicrob. Agents Chemother. 63:pii: e01110-18.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_4_29_2","unstructured":"WHO. 2017. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research Discovery and Development of New Antibiotics. World Health Organization. Available at https:\/\/www.who.int\/medicines\/publications\/global-priority-list-antibiotic-resistant-bacteria\/en"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq408"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2010.08.003"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02585-17"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38634-3"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2019.0075","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0075","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:35:32Z","timestamp":1777667732000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mdr.2019.0075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,1]]}},"alternative-id":["10.1089\/mdr.2019.0075"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2019.0075","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,1]]}}}